<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019899</url>
  </required_header>
  <id_info>
    <org_study_id>000153</org_study_id>
    <nct_id>NCT04019899</nct_id>
  </id_info>
  <brief_title>Myo-inositol and Vitamin D3 During IVF</brief_title>
  <official_title>Effects of Supplementation With Myo-inositol, Vitamin D3, Folic Acid and Melatonin on IVF Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of a multicomponent dietary supplement (myo-inositol, vitamin D3, folic acid
      and melatonin) to women undergoing IVF procedures.

      The aim of the study is to monitor the effects on the pregnancy, implantation and abortion
      rates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Single time-point: at 6 weeks of pregnancy</time_frame>
    <description>number of gestational sacs observed at ecographic screening divided by the number of embryos transferred</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocyte and embryo quality</measure>
    <time_frame>Single time-point: respectively, 12 days and 15 days after the beginning of Controlled Ovarian Hyperstimulation</time_frame>
    <description>Classification of the morphological aspects under the optical microscope</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>Single time-point: at 14 days from embryo transfer</time_frame>
    <description>Positive beta-hCG test after embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gemellarity</measure>
    <time_frame>Single time-point: at 6 weeks of pregnancy</time_frame>
    <description>Multiple gestational sacs observed at ecographic screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>Single time-point: at 6 weeks of pregnancy</time_frame>
    <description>Loss of pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of FSH IU used for controlled ovarian hyperstimulation</measure>
    <time_frame>Single time-point: about 10 days after the beginning of Controlled Ovarian Hyperstimulation</time_frame>
    <description>Ovarian ultrasound investigation and serum estradiol level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.
600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>study group</intervention_name>
    <description>2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.
600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;
600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI (kg/m2): 18.5 - 24.9

          -  basal FSH on day 3 &lt;15 mIU/ml

        Exclusion Criteria:

          -  presence of insulin resistance (IR)

          -  hyperglycaemia, hyperprolactinemia, hypothyroidism or androgen excess

          -  diagnosis of PCOS (according to Rotterdam ESHRE-ASRM Sponsored PCOS consensus workshop
             group)

          -  intake of hormones or drugs that can potentially influence the ovulation

          -  FSH&gt;15 on day 3
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinica Alma Res</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

